key: cord-1026951-n2if462c
authors: Du, Kang; Sun, Ling; Luo, Zichen; Cao, Yang; Sun, Qiushi; Zhang, Kangzhen; Faizy, Ahmed; Piomelli, Daniele; Lu, Xiang; Shan, Jinjun; Yang, Qin
title: Reduced DMPC and PMPC in lung surfactant promote SARS-CoV-2 infection in obesity
date: 2022-03-18
journal: Metabolism
DOI: 10.1016/j.metabol.2022.155181
sha: 02cc06d73b71a6b0a9a06beab5b79bcd710a54d9
doc_id: 1026951
cord_uid: n2if462c

OBJECTIVE: Obesity is an established risk factor for higher SARS-CoV-2 viral loads, severe COVID-19 pneumonia requiring hospitalization, and worse outcomes. However, the underlying mechanisms for the increased risk are not well understood. SARS-CoV-2 is a respiratory virus with the primary route of entry through the lungs, where the Spike protein of SARS-CoV-2 binds to the ACE2 receptor on pneumocytes. Lung surfactant produced by type II pneumocytes plays a major role in respiratory defense against infections. Surfactant predominantly contains lipids, especially phosphatidylcholines (PC), and obesity is characterized by aberrant lipid metabolism. We hypothesized that altered lipid composition in lung surfactant in obesity may promote SARS-CoV-2 infection, leading to severe COVID-19 disease. METHODS: Lipidomic analysis of lung tissue and bronchoalveolar lavage fluid (BALF) was performed using LC-MS/MS. The effects of PCs on SARS-CoV-2 pseudovirus infection were studied in HEK293T cells with ACE2 overexpression and in Vero-E6 cells with endogenous ACE2 expression. For the cell-cell fusion assay, HEK293T-ACE2 and HEK293T expressing SARS-CoV-2 Spike/eGFP were used as the target and effector cells, respectively. RESULTS: Lipidomic analysis revealed that myristic acid-containing dimyristoyl-PC (DMPC) and palmitoylmirystoyl-PC (PMPC) were reduced in lung tissue and BALF from high fat diet-induced obese mice. DMPC and PMPC markedly inhibited wild type and D614G mutant SARS-CoV-2 infection in HEK293T-ACE2 and Vero-E6 cells. Feeding obese mice with trimyristin, the triglycerides of myristic acid, increased DMPC and PMPC levels in lung surfactant. Lipid extract from BALF of trimyristin-treated obese mice mitigated the elevated wild type and D614G mutant SARS-CoV-2 infection. The inhibitory effects of DMPC and PMPC on SARS-CoV-2 infection were reversed by cholesterol. CONCLUSIONS: The reduced DMPC and PMPC in lung surfactant may promote SARS-CoV-2 infection. Increasing DMPC and PMPC in lung surfactant could be an innovative strategy for preventing and treating severe COVID-19 disease in obesity.

The ongoing COVID-19 pandemic caused by SARS-CoV-2 infection has led to more than 5 million deaths worldwide [1, 2] . Although it is well documented that obesity is a major risk factor for higher SARS-CoV-2 viral load, severe COVID-19 disease, and worse outcomes [3] [4] [5] , the underlying molecular mechanisms are not well understood. The proinflammatory status, impaired immune response, thrombogenic responses to pathogens, and dysregulation of the renin-angiotensin system may be involved [3] [4] [5] , but experimentally validated evidence for these mechanisms is limited.

COVID-19 is primarily a respiratory disease, and the initial viral entry is through the respiratory tract. The lungs are constantly exposed to microbes from aspiration. During evolution, the lung has developed dedicated defense systems to prevent infections. Surfactant produced by type II pneumocytes is a frontline of the lung host defense system [6] . Lung surfactant is a complex mixture of lipids and proteins, with approximately 90% lipids, predominantly phosphatidylcholines (PCs), and 10% proteins by mass [7, 8] . The main function of surfactant is to reduce surface tension at the air-liquid interface to prevent alveolar collapse. Surfactant also plays a key role in host defense against infection and inflammation. The lipophilic lung surfactant fraction has anti-microbial and anti-inflammatory properties when applied intratracheally to the lung as well as topically onto the skin [9, 10] .

Since obesity is characterized by aberrant lipid metabolism, we reasoned that altered lipid composition in lung surfactant may weaken its defense against SARS-CoV-2 infection. Our lipidomic analysis of lung tissue and surfactant revealed that dimyristoyl-phosphatidylcholine (DMPC) and palmitoylmirystoyl-phosphatidylcholine (PMPC) were reduced in obese mice.

Importantly, DMPC and PMPC inhibited wild type and D614G mutant SARS-CoV-2 infection. 

The obese mouse model was generated by feeding C57BL/6J male mice (Jackson Laboratory, Bar Harbor, ME, USA) with a high-fat diet (HFD) for 12 weeks starting from 8 weeks of age [11, 12] . For the trimyristin treatment, obese mice were fed the HFD containing 5%(wt/wt) trimyristin (J62819, Alfa Aesar, Tewksbury, MA, USA) for two weeks. Glucose and insulin tolerance tests were performed as described previously [11, 12] . All mouse studies were conducted in accordance with federal guidelines and were approved by the Institutional Animal Care and Use Committee of the University of California, Irvine.

The nontargeted lipidomic analysis of lung tissue and BALF was performed as described, and the data were processed using MS-DIAL (v. 2.78) software program [13] . The targeted lipid measurements used DMPC, PMPC and DPPC from Avanti as standards.

Two types of SARS-CoV-2 pseudovirus particles were generated for studying Spike-mediated viral infection. The first type was based on the single-cycle lentiviral system using plasmids J o u r n a l P r e -p r o o f Journal Pre-proof obtained from BEI Resources repository [14] . The second type of pseudotyped SARS-CoV-2 used the single-cycle vesicular stomatitis viruses (scVSVs) system [14, 15] . The mutant D614G SARS-CoV-2 Spike gene was obtained from Addgene (158075).

HEK293T cells with stable overexpression of ACE2 (HEK293T-ACE2) were kindly provided by Dr. Jesse D. Bloom [14] . Vero E6 cells were obtained from ATCC (CRL-1586). SARS-CoV-2 pseudoviruses with different concentrations of DMPC, PMPC and DPPC dissolved in ethanol were inoculated to HEK293-ACE2 or Vero E6 cells. After 24 hours of incubation, SARS-CoV-2 viral infection rates were detected by GFP positive cells or measured by luciferase activity (E1501, Promega, Madison, WI, USA). In the experiments using cholesterol, cells were preincubated with cholesterol for 2 hours before SARS-CoV-2 pseudovirus and lipids were added.

Cell-cell fusion assays were performed as described previously [16, 17] . Briefly, the target 

GraphPad Prism software (La Jolla, CA, USA) was used to analyze statistical differences. The two-tailed student's t-test was used to compare two groups, and the analysis of variance (ANOVA) test was used to compare three or more groups. Data were displayed as the mean ± standard error of the mean (SEM). Values of p< 0.05 were considered statistically significant.

HFD feeding markedly increased body weight, glucose, cholesterol and triglyceride levels, and impaired glucose and insulin tolerance (Supplementary Fig. 1A-1F) . BALF lipids from obese mice enhanced SARS-CoV-2 infection compared with lipids from lean control mice (Fig. 1A ) in both HEK293T with ACE2 overexpression and Vero E6 cells with endogenous ACE2 expression.

To identify potential lipids that promote SARS-COV-2 infection in obesity and diabetes, we performed nontargeted lipidomic analysis of lung tissue and BALF from obese and control lean mice [18] . The Principal Component Analysis showed that clustering of lipid profiles from obese and lean mice was readily separated under either the positive or negative ion mode (Supplementary Fig. 2A-2D) . HFD feeding significantly altered 95 lipids in the lung and 37 lipids in BALF compared with controls ( Supplementary Fig. 2E-2F) . Among the altered lipids, 8 were commonly reduced in lung and BALF, while none was commonly increased (Fig. 1B) . [19, 20] and another myristic acid containing PC (DMPC, 14:0-14:0) was one of the most reduced lipids in obese BALF, we performed targeted lipidomic studies using the standard compounds. We confirmed that DMPC and PMPC, but not the most abundant DPPC, were reduced in BALF of diet-induced obese mice (Fig. 1C-1E) .

Lysophosphatidylcholine acyltransferases (LPCAT1-4) were not altered in the lung of dietinduced obese mice (Supplementary Fig. 3) , suggesting the Land cycle is not involved in regulating DMPC and PMPC levels [21] .

We then tested the effects of DMPC and PMPC on SARS-CoV-2 infection using the pseudotyped virus system. Both DMPC and PMPC inhibited SARS-CoV-2 pseudovirus infection in HEK293T-ACE2 cells in a dose-dependent fashion. DMPC appeared to be more potent than PMPC (Fig. 1F-1G) , while DPPC had no effects on SARS-CoV-2 infection (Fig. 1H) . The pseudotyped SARS-CoV-2 also expressed GFP as a marker for virus infection. DMPC and PMPC, but not DPPC clearly reduced positive GFP cells (Fig. 1I) . Neither DMPC nor PMPC affected pseudotyped vesicular stomatitis virus (VSV) infection (Fig. 1J) , suggesting DMPC and PMPC specifically inhibited SARS-CoV-2 infection.

Similarly, DMPC and PMPC, but not DPPC inhibited SARS-CoV-2 infection in Vero E6 cells with endogenous ACE2 expression (Fig. 1K-1M) . D614G, the common mutation of the SARS-CoV-2 Spike protein in alpha, beta, gamma, and delta SARS-CoV-2 variants, has been reported to enhance virus replication and transmission [22, 23] . DMPC and PMPC also potently inhibited infection of SARS-CoV-2 pseudovirus harboring Spike D614G mutation in HEK293T-ACE2 and Vero E6 cells (Fig. 1N-1O) . Thus, DMPC and PMPC inhibit SARS-CoV-2 infection, which J o u r n a l P r e -p r o o f Journal Pre-proof provides initial evidence that reduced DMPC and PMPC in BALF may contribute to the increased SARS-CoV-2 infection in obesity and diabetes.

We designed two experiments to investigate whether increasing DMPC and PMPC in BALF may inhibit SARS-CoV-2 infection. First, since DMPC and PMPC were reduced in BALF of obese mice, we added DMPC and PMPC to BALF from obese mice and studied the effects on SARS-CoV-2 infection. In both HEK293T-ACE2 and Vero E6 cells, the addition of DMPC and PMPC to BALF from obese mice reversed the increased SARS-CoV-2 infection ( Fig. 2A-2B) . In the second approach, we treated the HFD-fed obese mice with trimyristin, triglycerides of C14:0 myristic acid, and a precursor for BALF DMPC and PMPC [20] . Two weeks of trimyristin treatment did not alter body weight or glucose levels ( Fig. 2C-2D) . BALF DMPC and PMPC were increased by 8.04 and 1.87 folds, respectively, while DPPC was reduced in the trimyristintreated obese mice (Fig. 2E-2G) . BALF from HFD-fed obese mice treated with trimyristin reversed the increased SARS-CoV-2 infection in HEK293T-ACE2 and Vero E6 cells (Fig. 2H-2I ). Importantly, trimyristin treatment also inhibited D614G mutant SARS-CoV-2 infection ( Figure 2J) . These results suggest that increasing BALF DMPC and PMPC may be a promising therapeutic strategy for preventing and treating SARS-CoV-2 infection.

The SARS-CoV-2 virus uses its Spike protein to bind ACE2 receptor on the cell surface to enter target cells. However, DMPC and PMPC did not affect Spike-ACE2 interaction ( Supplementary   Fig. 4) . Cholesterol comprises 30 mol % of lipids in the cell membrane and plays an essential role J o u r n a l P r e -p r o o f Journal Pre-proof in mediating SARS-CoV-2 entry to target cells [24] [25] [26] . Phosphatidylcholines are also the abundant phospholipids in the mammalian cell membrane [24, 25] . We reasoned that DMPC and PMPC may alter cell membrane cholesterol abundance to inhibit SARS-CoV-2 infection. Indeed, cholesterol dose-dependently reversed the inhibitor effects of DMPC and PMPC on SARS-CoV-2 infection in both HEK293T-ACE2 and Vero E6 cells (Fig. 2K-2L) . The role of cholesterol in regulating the inhibitory effects of DMPC and PMPC on SARS-CoV-2 infection is further studied in the standard cell-cell fusion assay, in which HEK293T cells expressing Spike-eGFP fusion protein serve as target cells, and HEK293T-ACE2 cells work as effector cells [16] . The interaction between Spike and ACE2 fuses the target and effector cells, resulting in syncytia formation [17, 25] . DMPC and PMPC disrupted the cell fusion between Spike and ACE expressing HEK293T. The effects were partially reversed by the addition of cholesterol (Fig. 2M-2N ). These results suggest that DMPC and PMPC may inhibit SARS-CoV-2 infection by replacing cell membrane cholesterol.

Since the outbreak of COVID-19 pandemic, epidemiological studies have provided convincing evidence that obesity is associated with higher SARS-CoV-2 viral loads, severe COVID-19 disease, and worse outcomes [3] [4] [5] . However, the underlying molecular mechanisms are not well understood. Lung surfactant is a frontliner of host defense against infections. Since obesity is to cultured cells [24, 29, 30] . Multiple clinical studies show that statin use is associated with a reduced risk of developing severe COVID-19 [31, 32] . The inhibitory effects of DMPC and PMPC on SARS-CoV-2 infection offer several potential therapeutic options for preventing or treating COVID-19 in obesity. We tested two approaches to increase DMPC and PMPC in the lung surfactant. In the first approach, adding DMPC or PMPC to BALF lipids extracted from obese mice reversed the increased SARS-CoV-2 infection. Natural surfactants from bovine or porcine lungs are FDA-approved drugs for treating pediatric J o u r n a l P r e -p r o o f and neonatal acute respiratory distress syndrome (ARDS) [33] . Although natural surfactants are not effective in treating ARDS in adults, DMPC and/or PMPC could be added to the natural surfactants with aerosolized/nebulized surfactant preparations for treating COVID-19, especially at the early phase, to prevent viral entry to cells. In the second approach, treating obese mice with trimyristin increased BALF DMPC and PMPC and inhibited SARS-CoV-2 infection.

Potentially, trimyristin could be used as a therapeutic agent to prevent or treat SARS-CoV-2 infection in obese patients. An alternative method is to treat bovine or porcine to increase DMPC and PMPC in the natural surfactants, which can be used for preventing SARS-CoV-2 infection.

The current study has several limitations. Although lipidomic analyses of pulmonary surfactant in humans with asthma, cystic fibrosis and ARDS are reported [34, 35] , the phospholipid profiles in human obesity have not been studied likely because it is too invasive to obtain lung surfactant for lipidomic analysis from obese patients. Future studies using obese primates will be informative. Trimyristin treatment of obese mice increases DMPC and PMPC in BALF, but we cannot exclude a possibility that other lipids may be involved in inhibiting SARS-CoV-2 infection. Finally, data interpretation should be limited to males because only male mice are used in this study.

In summary, our lipidomic analysis reveals that lung and surfactant DMPC and PMPC are reduced in obesity. Importantly, DMPC and PMPC inhibit both wild-type and D614G mutant 

The authors declare no conflict of interest.

Increased risk of infection with SARS-CoV-2 Beta, Gamma, and Delta variant compared to Alpha variant in vaccinated individuals

Heavily mutated Omicron variant puts scientists on alert

Global pandemics interconnected -obesity, impaired metabolic health and COVID-19

Association of Body Mass Index and Age With Morbidity and Mortality in Patients Hospitalized With COVID-19: Results From the American Heart Association COVID-19 Cardiovascular Disease Registry

Hospitalizations Attributable to Cardiometabolic Conditions in the United States: A Comparative Risk Assessment Analysis

Pulmonary surfactant: a front line of lung host defense

Current perspectives in pulmonary surfactant--inhibition, enhancement and evaluation

Structure-function relationships in pulmonary surfactant membranes: from biophysics to therapy

Effect of recombinant surfactant protein Cbased surfactant on the acute respiratory distress syndrome

Anterograde regulation of mitochondrial genes and FGF21 signaling by hepatic LSD1

Mechanosensitive Ion Channel Piezo1 Regulates Diet-Induced Adipose Inflammation and Systemic Insulin Resistance

Surfactant Lipidomics of Alveolar Lavage Fluid in Mice Based on Ultra-High-Performance Liquid Chromatography Coupled to Hybrid Quadrupole-Exactive Orbitrap Mass Spectrometry

Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays

Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant

A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike

Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion

Potential Therapeutic Applications of Pulmonary Surfactant Lipids in the Host Defence Against Respiratory Viral Infections

Lipidomics of cellular and secreted phospholipids from differentiated human fetal type II alveolar epithelial cells

Myristate is selectively incorporated into surfactant and decreases dipalmitoylphosphatidylcholine without functional impairment

Metabolites as regulators of insulin sensitivity and metabolism

Spike mutation D614G alters SARS-CoV-2 fitness

SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity

Cholesterol 25-Hydroxylase inhibits SARS-CoV-2 and other coronaviruses by depleting membrane cholesterol

SARS-CoV-2 requires cholesterol for viral entry and pathological syncytia formation

Oxysterols provide innate immunity to bacterial infection by mobilizing cell surface accessible cholesterol

Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2

Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Lipid rafts are involved in SARS-CoV entry into Vero E6 cells

Lipid rafts play an important role in the early stage of severe acute respiratory syndrome-coronavirus life cycle

Statin Use and In-Hospital Mortality in Patients With Diabetes Mellitus and COVID-19

Relation of Statin Use Prior to Admission to Severity and Recovery Among COVID-19 Inpatients

Surfactant therapies for pediatric and neonatal ARDS: ESPNIC expert consensus opinion for future research steps

Pulmonary surfactant in health and human lung diseases: state of the art

Lung surfactant in subacute pulmonary disease

lipids (25g/ml) from diet-induced obese mice enhance pseudotyped SARS

The pseudotyped SARS-CoV-2 virus particles are generated by transfecting Lenti-X™ 293T cells with plasmids obtained from BEI Resources repository: SARS-CoV-2 Spike (NR-52514)

NR-52516). The Spike protein on the pseudotype virus serves as a ligand for viral internalization into HEK293T and Vero E6 with ACE2 expression

The luciferase activity is measured as a surrogate for the viral infection rates. B. Commonly altered lipids in lung and BALF of diet-induced obese and control lean mice. C-E. DMPC, PMPC, and DPPC levels measured by targeted lipidomics in BALF from chow or HFD-fed mice

The pseudotyped SARS-CoV-2 viral particles express ZsGreen reporter, allowing the visualization of GFP fluorescence as an indicator for the viral infection. DMPC, PMPC, or DPPC lipids are dissolved in ethanol, and the same volume of ethanol was used as a control

N-O. DMPC and PMPC inhibit the infection of SARS-CoV-2 pseudovirus harboring Spike D614G mutation in 293T/ACE2 (N) and Vero E6 (O) cells (n=6). *P<0.05

Adding DMPC or PMPC to BALF lipid extraction from obese mice reverses the elevated SARS-CoV-2 infection in 293T/ACE2 (A) and Vero E6 cells (B) (n=4). C-D

Bodyweight (C) and glucose levels (D) in mice fed with chow, HFD, or HFD with trimyristin for two weeks (n=5-10). E-G. Trimyristin treatment increases DMPC (E) and PMPC (F) but reduces DPPC (G) in BALF of HFD-fed obese mice (n=5-8). H-I. BALF lipids from trimyristin-treated obese mice reverse the elevated SARS-CoV-2

After 24 hours of incubation, SARS-CoV-2 viral infection rates are measured by luciferase activity. M. DMPC and PMPC disrupt cell fusion between Spike and ACE2-expressing HEK293T, and the effects are reversed by the addition of cholesterol (n=5). *P<0.05. N. Representative cell fusion assay showing cholesterol reverses the DMPC and PMPC-inhibited cell fusion between Spike-eGFP and ACE2-expressing HEK293T cells (scale bars, 1000m)